Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded down 4.5% on Tuesday . The company traded as low as $68.32 and last traded at $68.55, with a volume of 506,314 shares traded. The stock had previously closed at $71.80.

A number of analysts recently weighed in on the stock. Leerink Swann restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 19th. Needham & Company LLC restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, June 13th. JMP Securities restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, July 10th. Credit Suisse Group AG restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, June 30th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $115.75.

The company’s market capitalization is $6.04 billion. The firm has a 50 day moving average of $61.45 and a 200 day moving average of $63.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.05) by $0.16. During the same quarter in the prior year, the firm posted ($0.62) EPS. The company earned $7.30 million during the quarter, compared to analyst estimates of $7.79 million. The business’s revenue for the quarter was down 60.4% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals Inc. will post ($4.94) EPS for the current year.

In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the sale, the chief executive officer now directly owns 148,465 shares in the company, valued at approximately $9,604,200.85. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Several large investors recently made changes to their positions in ALNY. Sei Investments Co. increased its stake in shares of Alnylam Pharmaceuticals by 493.7% in the fourth quarter. Sei Investments Co. now owns 19,569 shares of the biopharmaceutical company’s stock valued at $1,842,000 after buying an additional 16,273 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 0.4% in the fourth quarter. Mutual of America Capital Management LLC now owns 21,637 shares of the biopharmaceutical company’s stock valued at $2,037,000 after buying an additional 87 shares during the last quarter. Gulf International Bank UK Ltd increased its stake in shares of Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock valued at $2,175,000 after buying an additional 220 shares during the last quarter. Advisors Asset Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the fourth quarter. Advisors Asset Management Inc. now owns 64,827 shares of the biopharmaceutical company’s stock valued at $6,103,000 after buying an additional 226 shares during the last quarter. Finally, BlackRock Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 8.2% in the fourth quarter. BlackRock Advisors LLC now owns 179,529 shares of the biopharmaceutical company’s stock valued at $16,901,000 after buying an additional 13,612 shares during the last quarter.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.